Volume: 43 Issue: 1
Year: 2023, Page: 310-316, Doi: https://doi.org/10.51248/.v43i01.1537
Introduction and Aim: Cardiovascular disease are a leading cause of death in the world. Atherosclerosis plays the most important role in its pathophysiology. It is a slowly progressing chronic inflammatory process resulting in increased levels of inflammatory markers in serum. hs-CRP is a novel biomarker of coronary heart disease risk prediction. Type 2 diabetes mellitus individuals are at an increased risk of developing cardiovascular diseases. In this study, we aim to find the association of HbA1c with hs-CRP in the South Indian population.
Materials and Methods: This was a retrospective study. The study participants were categorised into 3 groups based on their serum hs-CRP levels: Group 1 with hs-CRP < 1.0 mg/L; group 2 with hs-CRP 1.0 – 3.0 mg/L and group 3 with hs-CRP > 3.0 mg/L. The sample size was estimated to be 40 for each group. Age, fasting blood glucose, postprandial blood glucose, HbA1c, hs-CRP, total count, and ESR were collected. Statistical analyses were performed with SPSS version 16.0.
Results: Age showed no significant difference among the groups. FBS, PPBS, HbA1c, TLC, and ESR showed a significant difference among the 3 groups. TLC, FBS, PPBS, and HbA1c had a significant positive correlation with hs-CRP.
Conclusion: hs-CRP has a statistically significant positive correlation with HbA1c, fasting blood sugar, and postprandial blood sugar Additionally, we also observed that total leukocyte count had a significant positive correlation with hs-CRP and HbA1c. Hence, our results show that impaired glycemic control is associated with an increased risk of developing cardiovascular diseases.
Keywords: HbA1c; hs-CRP; cardiovascular risk
1. Pahwa, R., Goyal, A., Bansal, P., Jialal, I. Chronic Inflammation. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Jan 17]
2. Prabhakaran, D., Jeemon, P., Roy, A. Cardiovascular Diseases in India: Current Epidemiology and Future Directions. Circulation. 2016 Apr 19;133(16):1605-1620.
3. Ruhil, R. India has Reached on the Descending Limb of Tobacco Epidemic. Indian J Community Med. 2018 Sep;43(3):153-156.
4. Crowther, M.A. Pathogenesis of Atherosclerosis. Hematology. 2005 Jan 1;2005(1):436-441.
5. India diabetes report 2000-2045 [Internet][cited 2021 Dec9].
6. Henning, R.J. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiology. 2018 Nov; 14(6):491-509.
7. Shoelson, S.E., Lee, J., Goldfine, A.B. Inflammation and insulin resistance. J Clin Invest. 2006 Jul 3;116(7):1793-1801.
8. Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O., Criqui, M., et al., Markers of Inflammation and Cardiovascular Disease. Circulation. 2003 Jan 28;107(3):499-511.
9. Koenig, W., Sund, M., Fröhlich, M., Fischer, H.G., Löwel, H., Döring, A., et al., C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-242.
10. NACB LMPG Committee Members, Myers, G.L., Christenson, R.H.M., Cushman, M., Ballantyne, C.M., Cooper, G.R., et al., National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009 Feb;55(2):378-384.
11. Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O., Criqui, M., et al., Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511.
12. Verma, S., Li. S.H., Badiwala, M.V., Weisel, R.D., Fedak, P.W.M., Li, R.K., et al., Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002 Apr 23;105(16):1890-1896.
13. Florida MLK PharmD PGY-2 (Ambulatory Care) Pharmacy Resident Department of Pharmacotherapy & Translational Research College of Pharmacy University of Florida Gainesville. The Application of High-Sensitivity C-Reactive Protein in Clinical Practice: A 2015 Update [Internet]. [cited 2022 Jan 19]
14. Mank, V., Brown, K. Leukocytosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Jan 17].
15. Lee C.D., Folsom, A.R., Nieto, F.J., Chambless, L.E., Shahar, E., Wolf, D.A. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol. 2001 Oct 15;154(8):758-764.
16. Kannel W.B., Anderson, K., Wilson, P.W. White Blood Cell Count and Cardiovascular Disease: Insights from the Framingham Study. JAMA. 1992 Mar 4;267(9):1253.
17. Erikssen, G., Liestøl, K., Bjørnholt, J.V., Stormorken, H., Thaulow, E., Erikssen, J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J. 2000 Oct;21(19):1614-1620.
18. Park, C., Guallar, E., Linton, J.A., Lee, D.C., Jang, Y., Son, D.K., et al., Fasting glucose level and the risk of incident atherosclerotic cardiovascular diseases. Diabetes Care. 2013 Jul;36(7):1988-1993.
19. Lee, J.H., Han, K., Huh, J.H. The sweet spot: fasting glucose, cardiovascular disease, and mortality in older adults with diabetes: a nationwide population-based study. Cardiovascular Diabetology. 2020 Apr 1;19(1):44.
20. Donahue, R.P., Abbott, R.D., Reed, D.M., Yano, K. Post challenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987 Jun;36(6):689-692.
21. Lin, H.J., Lee, B.C., Ho, Y.L., Lin, Y.H., Chen, C.Y., Hsu, H.C., et al., Postprandial Glucose Improves the Risk Prediction of Cardiovascular Death Beyond the Metabolic Syndrome in the Nondiabetic Population. Diabetes Care. 2009 Sep;32(9):1721-1726.
22. Avogaro, A. Postprandial Glucose: Marker or Risk Factor? Diabetes Care. 2011 Sep 15;34(10):2333-2335.
23. Cavero-Redondo, I., Peleteiro, B., Álvarez-Bueno, C., Rodriguez-Artalejo, F., Martínez-Vizcaíno, V. Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis. BMJ Open. 2017 July 1; 7(7): e015949.
24. Greenland, P., Alpert, J.S., Beller, G.A., Benjamin, E.J., Budoff, M.J., Fayad, Z.A., et al., ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary. Circulation. 2010 Dec 21;122(25):2748-2764.
25. Beckman, J.A., Creager, M.A., Libby, P. Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management. JAMA. 2002 May 15;287(19):2570.
Anjana Vinod, M. Ganesh, A. Manikandan, Rakchna M. Relationship between serum high-sensitivity C-reactive protein (hs-CRP) and glycated hemoglobin (HbA1c) in South Indian population. Biomedicine: 2023; 43(1): 310-316